Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: An important safety issue with GH replacement therapy (GHRT) in hypopituitary patients with a history of a pituitary adenoma is the risk for tumour recurrence or enlargement. Design: Case–control study. Subjects and methods: We studied tumour progression rate in 121 patients with hypopituitarism on the basis of non-functioning pituitary adenomas (NFPA) receiving long-term GHRT. A group of 114 NFPA patients not receiving GHRT who were matched in terms of duration of follow-up, gender, age, age at diagnosis and radiotherapy status were used as a control population. The average duration of GHRT was 10±4 years (range 2–17). Results: In patients with a known residual adenoma, 63% had no detectable enlargement of tumour during the study. In patients who had no visible residual tumour prior to GHRT, 90% did not suffer from recurrence. In total, the 10-year tumour progression-free survival rate in patients with NFPA receiving GHRT was 74%. In the control population not receiving GHRT, the 10-year progression-free survival rate was 70%. Radiotherapy as part of the initial tumour treatment reduced the rate of tumour progression in both GHRT and non-GHRT patients to a similar extent. Conclusions: The rate of tumour progression was similar in this large group of GHRT patients and the control population not receiving GHRT. Our results provide further support that long-term use of GH replacement in hypopituitarism may be considered safe in patients with residual pituitary adenomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Self-citationGrowth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
Self-citationIncreased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Markussis, V., Beshyah, S. A., Johnston, D. G., Fisher, C., Nicolaides, A. N., & Sharp, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)92892-j · Cited by 390
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375
Cited by
Higham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 267
Self-citationHormone Replacement Therapy and Physical Function in Healthy Older Men. Time to Talk Hormones?
Giannoulis, M. G., Martin, F. C., Nair, K. S., Umpleby, A. M., & Sonksen, P. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1002 · Cited by 132
Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
“…regimens promote any tumor recurrence or re-growth (Frajese et al., 2001; Hatrick et al., 2002; www.frontiersin.org June 2013 | Volume 4 | Article 64 | 7 Chung et al., 2005, 2008; Jostel et al., 2005; Karavitaki et al., 2006; Buchfelder et al., 2007; Arnold et al., 2009; Olsson et al., 2009).”
BackgroundBoguszewski, M. C. S., Boguszewski, C. L., Chemaitilly, W., Cohen, L. E., Gebauer, J., Higham, C., Hoffman, A. R., Polak, M., Yuen, K. C. J., Alos, N., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1186 · Cited by 117
Self-citationvan Varsseveld, N. C., van Bunderen, C. C., Franken, A. A. M., Koppeschaar, H. P. F., van der Lely, A. J., & Drent, M. L. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1764 · Cited by 26
“1% in our entire study population was lower than those in the treatment and control groups of the three aforementioned studies (17, 19, 20).”
BackgroundMethodResultInfluential
Metadata
- Authors
- Olsson, D. S., Buchfelder, M., Schlaffer, S., Bengtsson, B.-Å., Jakobsson, K.-E., Johannsson, G., & Nilsson, A. G.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-11
- Volume
- 161
- Issue
- 5
- Pages
- 663-669
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2152537582
- Cited by
- 57
- References
- 5
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. https://app.cochat.ai/papers/10.1530/eje-09-0572
- The paper
- Olsson, D. S., Buchfelder, M., Schlaffer, S., Bengtsson, B.-Å., Jakobsson, K.-E., Johannsson, G., & Nilsson, A. G. (2009). Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. European Journal of Endocrinology. https://doi.org/10.1530/eje-09-0572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.